Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | HCN1 | O60741 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314667 | 0.99 | CTSG (0.32) | CTSGCMA1KCNH2ALKBH5FTO | |
| SCHEMBL3684589 | 0.92 | CMA1 (0.33) | CTSGCMA1KCNH2ACACBACACA | |
| SCHEMBL3686184 | 0.83 | ACACB (0.35) | CMA1ALKBH5FTOACACBACACA | |
| SCHEMBL3686129 | 0.80 | NPC1 (0.31) | CMA1ACACA | |
| SCHEMBL2309891 | 0.78 | CTSG (0.31) | CTSGCMA1 | |
| SCHEMBL2311338 | 0.77 | CMA1 (0.33) | CMA1GPR84C5AR1 | |
| SCHEMBL2309500 | 0.76 | CTSA (0.35) | CTSGCMA1GPR84C5AR1 | |
| SCHEMBL2314001 | 0.76 | CMA1 (0.39) | CTSGCMA1GPR84C5AR1 | |
| SCHEMBL2311149 | 0.75 | SLC6A2 (0.35) | CTSGCMA1GPR84C5AR1 | |
| SCHEMBL2359024 | 0.75 | C5AR1 (0.33) | C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2152674-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CTSG 26/4885CMA1 1/4885OPRM1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.